NCT05548556View on ClinicalTrials.gov

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

May 2, 2025

Study Completion Date

November 2, 2026

Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
DRUG

Placebo

Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)

DRUG

RO7204239

Participants will receive SC RO7204239 Q4W

Trial Locations (10)

2100

Rigshospitalet, København Ø

20162

Asst Grande Ospedale Metropolitano Niguarda, Milan

21205

Kennedy Krieger Institute, Baltimore

66205

University of Kansas Medical Center, Fairway

80045

Regents of the University of Colorado, Aurora

92868

University of Irvine Medical Center (UCIMC), Orange

23298-0599

Virginia Commonwealth University Medical Center, Richmond

00168

Policlinico Universitario Agostino Gemelli, Rome

WC1N 3BG

National Hospital for Neurology and Neurosurgery,, London

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY